anderson9.jpg Pamela W. Anderson
Columnista Experta de SIIC


Medical Advisor, Indianápolis, EE.UU.
EFECTOS DEL TRATAMIENTO CON RALOXIFENO O CON ESTROGENOS MAS PROGESTERONA SOBRE LOS PREDICTORES DE ENFERMEDAD VASCULAR ATEROTROMBOTICA EN MUJERES POSMENOPAUSICAS SANAS. INTERPRETACION DE LOS DATOS EN EL CONTEXTO DE LOS ESTUDIOS HERS Y WHI
Columnista Experta de SIIC Pamela W. Anderson en colaboración con Cox David A


Fecha de aprobación: 21 de octubre, 2003
Primera edición en siicsalud: 10 de diciembre, 2003
Sección Artículos originales, subsección Expertos de Iberoamérica,
página /des/expertocompleto.php/20065  
Especialidad principal: Especialidad principalObstetricia y Ginecología

Especialidades relacionadas:
Cardiología,Endocrinología y Metabolismo,Epidemiología,Farmacología,Medicina Farmacéutica,Medicina Interna,Obstetricia y Ginecología,

  • Anderson PW, Draper MW. 1997. Raloxifene—A novel selective receptor modulator (SERM) with potential cardioprotective effects in the postmenopausal woman, Clin Calcium 7:93-97, 1997

  • Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. 1998. The effects of raloxifene HCl on serum lipids and coagulation factors in healthy postmenopausal women, JAMA 279:1445-1451, 1998

  • Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW. 2000. The effects of raloxifene compared with hormone replacement therapy on homocysteine and C-reactive protein in healthy postmenopausal women: a randomized, controlled trial, J Clin Endo Metab 85:214-218, 2000

  • Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL,Walsh BW. 2001. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women., Maturitas 39:71-77, 2001

  • Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright T, Helterbrand J, Anderson PW. 2001. Design and methods of the Raloxifene Use For the Heart (RUTH) study, Amer J Cardiol 88:392-395, 2001

  • Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. 2001. Role of tumor necrosis factor-beta and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women, Am J Cardiology 88:825-828, 2001

  • Mosca L, Harper K, Sarkar S, O\'Gorman J, Anderson PW, Cox DA, Barrett-Connor E. 2001. Effect of raloxifene on serum triglycerides in postmenopausal women: Influence of predisposing factors for hypertriglyceridemia, Clin Ther 23(23):, 2001

  • Andersson B, Johannsson G, Holm G, Bengtsson B-A, Sashegyi A, Pavo I, Mason T, Anderson PW. 2002. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial, J Clin Endo and Metab 87:122-128, 2002


  • Pamela W. Anderson

    ua40317